Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, September 6, 2026

Back to today

From X

@BrokenMoats

Broken Moats on X

Continue to believe that expiration this week will be the culmination in the software squeeze. Money will want to come off the table ahead of earnings season for the sector, and I think that will be followed with an acknowledgment from earnings that while their revenues are not at risk today - these companies still do face increased competition, lower barriers, higher costs for cloud/inference, and seat based model problems that will be challenging moving forward. The $WDAY rumor news was not the floor, it was the peak counter narrative to AI disruption.
@BrokenMoats

Broken Moats on X

Impressive just how many healthcare companies with no direct or derivative exposure today or at any point to the $MRNA news can rally 10%+ on the day. Be smart for these companies to pocket these gains with secondaries and solidify fragile balance sheets, but in the ultimate short term pump market their management teams will no doubt not want to interrupt their stocks squeeze potential and will not issue shares, but aggressively unload their options
@BlueDuckCap 1 click

BDC on X

Could happen. Also - there will be a massive 2ndary soon and insiders will start dumping shares. I wish this was a cure for cancer. It is not. If it ever even commercializes (still a big if) it will be just another thearaputic that will be sold along with Keytruda and in some cases may deter relapse. That's it. In fact, we may learn that the same lipid nano particles that the mrna technology relies on and which have been speculated to be a cancer causer in their own right (hint, they are) actually cause occurence of other cancers such as colon and pancreatic and breast. Does lowering recurrence in melanoma in exchange for a higher chance of colon cancer sound like a "cure"? I wish it was. No material position as of now. Congrats to bulls, I guess. $MRNA

Investor Letters

All letters

Dollar Tree: Weathering The Storm

Dollar Tree’s $1.25 opening price and multi-price assortment supported 10% two-year comparable-sales growth, outpacing Walmart U.S.

DLTR $21B
TSOH Investment Research 1 click
MOH · long

Molina Healthcare

Molina Healthcare faces unprecedented Medicaid managed-care cost inflation and margin compression after its shares declined since October…

MOH $11B
Value Investors Club

TSOH Weekly Roundup (08/28/2026)

TSOH Weekly Roundup tracks Dick’s Sporting Goods’ Foot Locker setback and Brown-Forman’s internal debate over a potential Pernod Ricard…

DKS $11B
TSOH Investment Research

QXO Inc.

QXO is building a North American construction-products distributor through Beacon, Kodiak and TopBuild, targeting $18.1 billion of combined…

QXO $12B
SixSigmaCapital: Navigating the Financial Markets

Core Memory

Airbnb Experiences faces a supply bottleneck from manual approvals, while a farm host raised her price from $15 to $25 after stronger…

ABNB $99B
MBI Deep Dives 9 clicks

Publications we follow

Every publication on this site, hand-picked.

108 publications

Newsletters 91

YouTube 4

Blogs 12

Seeking Alpha 29 of 159

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

68 accounts
Nominate an account

Investor letters we follow

78 firms

Sectors

Ordered by how often our editor reaches for them.